Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nobilonine in preparing drugs for resisting multiple myeloma

A multiple myeloma, dendrobium ketone base technology, applied in the field of biomedicine, can solve the problems of conventional chemotherapy, the effective rate is not ideal, less than 5%, and the median survival period is not more than 3 years.

Inactive Publication Date: 2020-01-17
南京乐扬医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Without treatment, the median survival period of patients with advanced MM is only 6 months; the effective rate of conventional chemotherapy is 40% to 60%, the complete remission rate is less than 5%, and the median survival period is no more than 3 years; 25% of patients survive more than 5 years, and less than 5% of MM survive 10 years
[0003] The reason why the effective rate of conventional chemotherapy is not ideal is that the curative effect of chemotherapeutic drugs needs to be improved. Therefore, it is a hot spot in this field to find and develop drugs with high curative effect on multiple myeloma and to improve the effective rate of chemotherapy.
There is no report on the use of dendrobium in the treatment of multiple myeloma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nobilonine in preparing drugs for resisting multiple myeloma
  • Application of nobilonine in preparing drugs for resisting multiple myeloma
  • Application of nobilonine in preparing drugs for resisting multiple myeloma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Proliferation inhibitory effect on human multiple myeloma U266 cells

[0016] 1. Test materials

[0017] Human multiple myeloma U266 cells were purchased from ATCC. Penicillin, MTT, and dimethyl sulfoxide were purchased from Sigma. The HPLC purity of dendrobone base is more than or equal to 98%. Fetal bovine serum was purchased from Gibco, and RPMI 1640 medium was purchased from Solarbio.

[0018] 2. Test method

[0019] 1. Cell culture and grouping

[0020] U266 cells were cultured in RPMI 1640 containing 15% fetal bovine serum, 100 U / ml penicillin and 100 μg / ml streptomycin based on 5% CO 2 , cultured and passaged in a 37°C incubator, and the logarithmic phase cells were taken for subsequent experiments.

[0021] Grouped as follows:

[0022] Dendrobine low concentration group: cultured with RPMI 1640 containing 15% fetal bovine serum, 100U / ml penicillin, 100μg / ml streptomycin, 10nM dendrobine based on 5% CO 2 , Cultivated in a 37°C incubator;

[00...

Embodiment 2

[0034] Example 2: Proliferation inhibitory effect on human multiple myeloma LP-1 cells

[0035] 1. Test materials

[0036] Human multiple myeloma LP-1 cells were purchased from ATCC. Penicillin, MTT, and dimethyl sulfoxide were purchased from Sigma. The HPLC purity of dendrobone base is more than or equal to 98%. Fetal bovine serum was purchased from Gibco, and RPMI 1640 medium was purchased from Solarbio.

[0037] 2. Test method

[0038] 1. Cell culture and grouping

[0039] LP-1 cells were cultured in RPMI 1640 containing 10% fetal bovine serum, 100 U / ml penicillin, 100 μg / ml streptomycin based on 5% CO 2 , Cultured in a 37°C incubator, subcultured every 2-3 days, and the logarithmic phase cells were taken for subsequent experiments.

[0040] Grouped as follows:

[0041] Dendrobium low concentration group: cultured with RPMI 1640 containing 10% fetal bovine serum, 100U / ml penicillin, 100μg / ml streptomycin, 10nM dendrobine based on 5% CO 2 , Cultivated in a 37°C incub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of nobilonine in preparing drugs for resisting multiple myeloma; the test result shows that the nobilonine can effectively inhibit the proliferation of human multiple myeloma cell, has obvious dose dependence, and can be developed into a drug for resisting human multiple myeloma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the use of dendrobium ketone base for preparing anti-multiple myeloma drugs. Background technique [0002] Multiple myeloma (MM) is a malignant tumor of plasma cells, characterized by the clonal proliferation and accumulation of plasma cells in the bone marrow, and the secretion of monoclonal immunoglobulin or its fragments (M protein), accompanied by Extensive osteolytic lesions or osteoporosis and clinical manifestations such as anemia, infection, and renal impairment. Without treatment, the median survival period of patients with advanced MM is only 6 months; the effective rate of conventional chemotherapy is 40% to 60%, the complete remission rate is less than 5%, and the median survival period is no more than 3 years; 25% of patients survived for more than 5 years, and less than 5% of MM survived for 10 years. [0003] The reason why the effective rate of conventional chemotherapy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P35/00
CPCA61K31/365A61P35/00
Inventor 周天北
Owner 南京乐扬医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com